Sebastien Beauzile, a 21-year-old from New York, has achieved remission from sickle cell disease following treatment with Lyfgenia, a gene therapy developed by Bluebird Bio, at Northwell Health/Cohen Children’s Medical Center. Administered on December 17, 2024, the therapy has resulted in the absence of disease symptoms, representing a significant advancement in sickle cell disease treatment.
Sebastien, who lived with sickle cell disease for over two decades, experienced severe chest, back, and joint pain, as well as skin ulcers. Cohen Children’s Medical Center became the first hospital in New York State to administer Lyfgenia.
Lyfgenia, along with Casgevy (Vertex Pharmaceuticals), received FDA approval in late 2023 for patients aged 12 and older, based on robust clinical trial data. In the Lyfgenia trial (NCT02140554), 88% of 32 patients experienced symptom resolution within 6 to 18 months.
“Growing up with sickle cell, it’s been a constant presence,” Sebastien stated. “Being cured feels like a new birthday; nothing can stop me now.”
Sickle cell disease, an inherited blood disorder affecting approximately 100,000 people in the U.S., primarily African Americans, is caused by a hemoglobin mutation. This mutation leads to sickle-shaped red blood cells, obstructing blood flow and oxygen delivery. Vaso-occlusive events (VOEs) can cause severe pain and organ damage, leading to long-term disability or premature death.
Traditional management includes medical treatments and bone marrow transplants, which require compatible donors and immunosuppression.
Lyfgenia utilizes a patient’s own bone marrow, inserting a healthy hemoglobin gene and reintroducing the modified cells. This process enables the patient’s body to produce healthy blood cells, eliminating rejection risk and the need for immunosuppressants.
“Sebastien’s recovery is remarkable, and we hope he is the first of many patients we treat with Lyfgenia,” said Charles Schleien, MD, senior vice president of Cohen Children’s Medical Center.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
